First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.
Blagden, Sarah
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Dec 2014 - 5908-17 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
1557-3265
10.1158/1078-0432.CCR-14-1315 doi
Administration, Oral
Adult
Aged
Antineoplastic Agents--pharmacology
Class I Phosphatidylinositol 3-Kinases--antagonists & inhibitors
Dose-Response Relationship, Drug
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Metastasis
Neoplasms--diagnosis
Positron-Emission Tomography
Pyrimidines--pharmacology
Sulfonamides--pharmacology
Tomography, X-Ray Computed
Treatment Outcome
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Dec 2014 - 5908-17 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
1557-3265
10.1158/1078-0432.CCR-14-1315 doi
Administration, Oral
Adult
Aged
Antineoplastic Agents--pharmacology
Class I Phosphatidylinositol 3-Kinases--antagonists & inhibitors
Dose-Response Relationship, Drug
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Metastasis
Neoplasms--diagnosis
Positron-Emission Tomography
Pyrimidines--pharmacology
Sulfonamides--pharmacology
Tomography, X-Ray Computed
Treatment Outcome